Severe skin lesions cause patients with inflammatory bowel disease to discontinue anti-tumor necrosis factor therapy.
about
Onset of psoriasis in patients with inflammatory bowel disease treated with anti-TNF agentsParadoxical reactions under TNF-α blocking agents and other biological agents given for chronic immune-mediated diseases: an analytical and comprehensive overviewUstekinumab for the treatment of Crohn's disease.Frequency, phenotype, outcome, and therapeutic impact of skin reactions following initiation of adalimumab therapy: experience from a consecutive cohort of inflammatory bowel disease patients.Adverse events in IBD: to stop or continue immune suppressant and biologic treatmentBiological therapy for dermatological manifestations of inflammatory bowel diseaseA study investigating the association of dermatological and infusion reactions to infliximab and infliximab trough levels.Long-term ustekinumab therapy of psoriasis in patients with coexisting rheumatoid arthritis and Sjögren syndrome. Report of two cases and review of literature.Genetic basis of TNF-α antagonist associated psoriasis in inflammatory bowel diseases: a genotype-phenotype analysis.Paradoxical Autoinflammatory Skin Reaction to Tumor Necrosis Factor Alpha Blockers Manifesting as Amicrobial Pustulosis of the Folds in Patients With Inflammatory Bowel Diseases.Infliximab-Associated Psoriasiform Dermatitis: Case Report and Review of a Seemingly Paradoxical Inflammatory Response.The onset of psoriasis during the treatment of inflammatory bowel diseases with infliximab: should biological therapy be suspended?Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 3: special situations.Anti-TNF-alpha induced psoriasiform eruptions with severe scalp involvement and alopecia: report of five cases and review of the literature.Mechanisms of action of anti-tumor necrosis factor α agents in Crohn's disease.Immune-mediated inflammatory reactions and tumors as skin side effects of inflammatory bowel disease therapy.Immune-mediated reactions to anti-tumor necrosis factors in inflammatory bowel disease.Safety of infliximab for the treatment of inflammatory bowel disease: current understanding of the potential for serious adverse events.Long-term safety and efficacy of certolizumab pegol in the treatment of Crohn's disease: 7-year results from the PRECiSE 3 study.Biologic agents for IBD: practical insights.Balancing the risks and benefits of biologic therapy in inflammatory bowel diseases.A safety assessment of anti-tumor necrosis factor alpha therapy for treatment of Crohn's disease.Adverse Events During Anti-TNFα Therapies in IBD (Excluding Infections and Malignancies): When to Stop, Continue, or Switch Therapies.Clinical Signs, Pathophysiology and Management of Cutaneous Side Effects of Anti-Tumor Necrosis Factor Agents.Serum Concentration of Anti-TNF Antibodies, Adverse Effects and Quality of Life in Patients with Inflammatory Bowel Disease in Remission on Maintenance Treatment.Psoriasiform Skin Lesions Are Caused by Anti-TNF Agents Used for the Treatment of Inflammatory Bowel Disease.Paradoxical psoriasis in a large cohort of patients with inflammatory bowel disease receiving treatment with anti-TNF alpha: 5-year follow-up study.Successful Treatment of Ulcerative Colitis With Vedolizumab in a Patient With an Infliximab-Associated Psoriasiform Rash.Anti-TNF and skin inflammation in IBD: a new paradox in gastroenterology?Skin Manifestations of Inflammatory Bowel Disease.The incidence and predictors of lupus-like reaction in patients with IBD treated with anti-TNF therapies.Tumor necrosis factor α antagonist-associated psoriasis in inflammatory diseases: an analysis of the FDA adverse event reporting system.Digestive system in psoriasis: an update.Impact of vedolizumab therapy on extra-intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the OBSERV-IBD cohort.Paradoxical psoriasiform reactions of anti-tumour necrosis factor therapy in inflammatory bowel disease patients.Induction or exacerbation of psoriasis in patients with Crohn's disease under treatment with anti-TNF antibodies.Association Between Infliximab Trough Levels and the Occurrence of Paradoxical Manifestations in Patients with Inflammatory Bowel Disease: a Case-Control Study.Development of psoriasis in IBD patients under TNF-antagonist therapy is associated neither with anti-TNF-antagonist antibodies nor trough levels.Anti-TNF associated psoriasis.Concomitant use of azathioprine/6-mercaptopurine decreases the risk of anti-TNF-induced skin lesions.
P2860
Q22305935-190E39F8-A6B1-44DC-94CD-2166120672C0Q26738918-02762DD4-8745-4114-A0F3-D9F02D48C115Q30390909-4107B30C-66DE-42F8-A2E8-C626576FEAE9Q33829739-25163D1A-EF0B-45EC-84D3-A46FE3D38AADQ34073191-21564ABC-CB24-4D5F-A3A4-FA0AA5A0C60CQ35058744-B02BA127-42C1-450A-8017-92601F463879Q35100143-122DBECE-7D7B-4BA7-B82C-F59076D50A1FQ36202783-B2779BB9-F6DC-46FA-8D6F-17C6FADCDF20Q36586054-B0A50328-634E-414D-B06E-49C02AB8FB01Q37016608-9843789D-9399-44E4-849B-AF4956A3BF01Q37329074-2F48D164-27E2-4619-BB78-58E4A2828F13Q38024281-B9A81939-34A8-4052-9F97-56A4CAC5FDCDQ38049779-E1744873-7868-431A-A913-911D32229B3DQ38050938-50ADFAEE-27B6-46DF-91FE-65A10B259C50Q38099727-5C43404D-CA21-4E0A-A1AE-5A9CFECC2649Q38179468-BD46D017-8039-4FC0-9C07-47DC969FF1F9Q38315640-7B3A2E74-372E-445A-9D42-663A66EB2B0FQ38394816-F0BD0198-1658-4039-A5DC-88A751A87425Q38425063-C245536F-5CC4-4AC3-80EA-769E0B615F5BQ38568898-E0A27631-F38A-434F-AF31-9F6F3F03BDADQ38630959-06CAF683-18E8-45CF-AB2D-3617B46D9D59Q38707864-85AE2BA9-0E8A-4AD0-92E2-8988C8416757Q38751610-51D648D4-C990-4B5A-B87F-C6A2167F5675Q39361308-3C69840F-979B-4888-98D7-B41FEA20563CQ40791552-239F568B-2A74-4CBC-B137-D974D9F2077EQ40792685-A5E27E4D-1903-44E6-BF1D-ACA1460BD57BQ41520678-D3AAB961-34C5-4E4A-9388-D13811E73388Q42074843-3587BAE3-7519-42F5-8E89-6B25FB90968BQ44379124-F238ACA1-304E-4448-B55C-7B3B34F23429Q44390503-A4A217BC-54FA-4045-8269-FA239F2D0370Q44803722-F1E913D8-2734-4566-A540-2624EFCA0C43Q45062333-28C9ECB0-7BE6-4834-A5F0-377602E348D9Q46466020-00AB4109-D900-4EF9-B3E1-C77C1CC67297Q48102896-BD4374B6-8F3D-4692-8CC2-09EFEA678B1BQ49970991-25F6A448-DD65-4E2E-998B-E14D61400C28Q50681708-6C19381E-40F7-49EA-A769-C1FA98DF432FQ50986864-E9DC941A-C0A1-4C5E-ABB0-0F15522B033AQ51565778-5E33C692-014D-41E5-A0F0-5FD712D2DBBDQ52844436-A56DC6F4-5847-4E58-9CAD-B079F770A0FEQ53228858-B9B278EE-806A-44C8-A14D-BF95DF438561
P2860
Severe skin lesions cause patients with inflammatory bowel disease to discontinue anti-tumor necrosis factor therapy.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Severe skin lesions cause pati ...... tumor necrosis factor therapy.
@en
Severe skin lesions cause pati ...... tumor necrosis factor therapy.
@nl
type
label
Severe skin lesions cause pati ...... tumor necrosis factor therapy.
@en
Severe skin lesions cause pati ...... tumor necrosis factor therapy.
@nl
prefLabel
Severe skin lesions cause pati ...... tumor necrosis factor therapy.
@en
Severe skin lesions cause pati ...... tumor necrosis factor therapy.
@nl
P2093
P50
P1476
Severe skin lesions cause pati ...... tumor necrosis factor therapy.
@en
P2093
Bernard Duclos
David Laharie
Edouard Louis
Emmanuel Delaporte
Groupe d'Etude Thérapeutique des Affections Inflammatoires du Tube Digestif (GETAID)
Jacques Cosnes
Jean-François Rahier
Jean-Marie Reimund
Marc Lémann
Matthieu Allez
P304
P356
10.1016/J.CGH.2010.07.022
P407
P577
2010-08-20T00:00:00Z